Mirae Asset Global Investments Co. Ltd. Acquires 533 Shares of BioNTech SE Sponsored ADR $BNTX

Mirae Asset Global Investments Co. Ltd. increased its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 14.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,109 shares of the company’s stock after purchasing an additional 533 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in BioNTech were worth $437,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. BNP Paribas Financial Markets grew its stake in shares of BioNTech by 94.6% in the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after purchasing an additional 581,173 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock worth $63,593,000 after purchasing an additional 694,691 shares during the last quarter. Invesco Ltd. grew its stake in shares of BioNTech by 643.7% in the first quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock worth $58,747,000 after purchasing an additional 558,389 shares during the last quarter. Millennium Management LLC grew its stake in shares of BioNTech by 252.5% in the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after purchasing an additional 390,360 shares during the last quarter. Finally, LBP AM SA boosted its position in BioNTech by 20.7% during the first quarter. LBP AM SA now owns 305,221 shares of the company’s stock valued at $27,793,000 after acquiring an additional 52,303 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BNTX. Morgan Stanley cut their price target on shares of BioNTech from $133.00 to $131.00 and set an “overweight” rating on the stock in a research report on Friday. JPMorgan Chase & Co. upped their price target on shares of BioNTech from $116.00 to $121.00 and gave the company a “neutral” rating in a research report on Monday, September 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioNTech in a research report on Saturday, September 27th. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the company an “overweight” rating in a research report on Tuesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $136.00 price target on shares of BioNTech in a research report on Monday, September 8th. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $134.32.

BioNTech Trading Down 2.3%

BNTX opened at $102.06 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $129.27. The firm has a market capitalization of $24.54 billion, a PE ratio of -63.79 and a beta of 1.45. The company’s 50-day moving average is $104.48 and its 200 day moving average is $103.52.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company’s revenue was up 102.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, research analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.